Potassium perchlorate API Manufacturers

General Description:

Potassium perchlorate, identified by CAS number 7778-74-7, is a notable compound with significant therapeutic applications. Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. Potassium is most commonly used in flares and automobile airbags . The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry . Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone. Thus the use of potassium perchlorate has been extensive for hyperthyroidism during the last 50 years, particularly in the late 1950s and early 1960s . The therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome .

Indications:

This drug is primarily indicated for: No current FDA- or EMA-approved therapeutic indications. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Potassium perchlorate undergoes metabolic processing primarily in: Perchlorate ions are not reported to undergo metabolism . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Potassium perchlorate are crucial for its therapeutic efficacy: Perchlorate is rapidly absorbed from the gastrointestinal (GI) tract after ingestion . The time to reach peak plasma levels of perchlorate is approximately 3 hours following oral administration . As potassium perchlorate is an organic compound with complete ionization in water, dermal absorption through intact skin is unlikely . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Potassium perchlorate is an important consideration for its dosing schedule: Perchlorate has a half-life in humans of approximately 6 to 8 hours . This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Potassium perchlorate exhibits a strong affinity for binding with plasma proteins: Displacement studies with thyroid hormones suggest that perchlorate ions may interfere with the binding of T4 to serum proteins . This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Potassium perchlorate from the body primarily occurs through: Perchlorate is mainly excreted unchanged in the urine with the recovery rate of approximately 95% within 72 hours . It is reported that half of the total perchlorate ions administered orally are excreted during the first 5 hours post-dosing while the rest of the dose is excreted within 48 to 72 hours . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Potassium perchlorate is distributed throughout the body with a volume of distribution of: No pharmacokinetic data on the volume of distribution. Perchlorate is likely to sequester into the thyroid gland, gastrointestinal tract, and possibly the skin . This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Potassium perchlorate is a critical factor in determining its safe and effective dosage: No pharmacokinetic data on clearance rate. Systemic clearance is biphasic with a slow terminal phase . It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Potassium perchlorate exerts its therapeutic effects through: Potassium perchlorate inhibits thyroid iodide transport. The clinical use of potassium perchlorate in hyperthyroidism, such as Graves' disease and amiodarone-induced hypothyroidism, have been investigated in various studies. Thyroid dysfunction occurs in about 15-20% of the patients receiving long-term amiodarone therapy . In patients with amiodarone-induced hypothyroidism, short-term administration of potassium perchlorate resulted in restoration of euthyroidism in most patients . Euthyroidism promoted by potassium perchlorate does not persist unless amiodarone treatment is withdrawn . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Potassium perchlorate functions by: Thyroxine (T4) and tri-iodothyronine (T3) are major thyroid hormones, or iodothyronines, that are synthesized and released from the thyroid. Iodine plays an essential role in the synthesis of these hormones. Via the sodium-iodide symporter (NIS), which is a protein located on the basolateral membrane of the thyroid follicular cell, iodine is transported from the blood into the thyroid gland where it is oxidized to . Perchlorate (ClO4−) is the dissociated anion of potassium perchlorate that exerts an inhibitory effect on iodide uptake by the thyroid gland in the cellular level . Due to its similarity in ionic size and charge to iodide, perchlorate inhibits the sodium-iodide symporter (NIS) without being translocated into the thyroid follicular cell . The inhibition constant, Ki, is estimated as 0.4 µmol to 24 µmol. At therapeutic dosage levels this competitive inhibition decreases the entrance of iodide into the thyroid, resulting in less available iodide for hormone synthesis and, therefore, a decrease in T3 and T4 synthesis . When ambient iodine intake is low or iodide uptake is sufficiently inhibited, perchlorate is capable in inducing goiter and hypothyroidism from inhibited iodide uptake . At high doses of potassium perchlorate, reduced T3 and T4 levels may be accompanied by increased TSH levels via a negative feedback loop, affecting the thyroid, pituitary and hypothalamus . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Potassium perchlorate belongs to the class of inorganic compounds known as alkali metal perchlorates. These are inorganic compounds in which the largest oxoanion is perchlorate, and in which the heaviest atom not in an oxoanion is an alkali metal, classified under the direct parent group Alkali metal perchlorates. This compound is a part of the Inorganic compounds, falling under the Mixed metal/non-metal compounds superclass, and categorized within the Alkali metal oxoanionic compounds class, specifically within the Alkali metal perchlorates subclass.

Categories:

Potassium perchlorate is categorized under the following therapeutic classes: Acids, Acids, Noncarboxylic, Antithyroid agents, Chlorine Compounds, Drugs that are Mainly Renally Excreted, Perchlorates, Potassium Salt, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroid Products. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Potassium perchlorate include:

• Water Solubility: 17 g/L at 20 °C
• Melting Point: Decomposes at 400 °C